The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes
Open accessThe DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.
Abstract
See Gordon and Tijms (doi:10.1093/brain/awz278) for a scientific commentary on this article. Jack et al. examine relationships between the bivariate distribution of β-amyloid and tau on PET and established neurocognitive clinical syndromes. Amyloidosis appears to be required for high levels of 3R/4R tau deposition. Whereas abnormal amyloid PET is compatible with normal cognition, highly abnormal tau PET is not.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Tau PET uptake occurs at a later stage and age than amyloid Pet and is more closely associated with cognitive dysfunction than amyloid-PET.(442, 443)”
From Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission (2024) · cites this paper as [443]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“robust evidence indicates that cerebral Aβ accumulation is one of the earliest mechanistic alterations of the whole pathophysiological dynamic of AD (104–107).”
From The β-Secretase BACE1 in Alzheimer’s Disease (2021) · cites this paper as [106]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, CSF and positron emission tomography longitudinal studies support the hypothetical pathophysiological model of AD for which amyloidosis proceeds, either promoting or being permissive to the spreading of tau pathology that is likely to drive disease clinical evolution (104–107).”
From The β-Secretase BACE1 in Alzheimer’s Disease (2021) · cites this paper as [106]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several genetic data studies (306 autosomal dominant mutations plus the APP gene duplication and trisomy 21) and multimodal biomarker studies indicate that an imbalance between Aβ production and clearance plays a critical and early role in AD pathogenesis (104–106,113,114).”
From The β-Secretase BACE1 in Alzheimer’s Disease (2021) · cites this paper as [106]
Experimental — accuracy not yet measuredIn the citing paper
“A large amount of evidence also supports the hypothesis that cerebral Aβ deposition begins decades before AD clinical onset and prior to cortical spreading of tau pathology.”
From The β-Secretase BACE1 in Alzheimer’s Disease (2021) · cites this paper as [106]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Self-citationNIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Self-citationAmyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)
Hu, R. J. (2003) · Encyclopedia of the Neurological Sciences · doi:10.1016/b0-12-226870-9/01070-4 · Cited by 9,117
Mild cognitive impairment as a diagnostic entity
Petersen, R. C. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01388.x · Cited by 7,864
Self-citationSensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia
Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhaus, J., van Swieten, J. C., Seelaar, H., Dopper, E. G. P., Onyike, C. U., et al. (2011) · Brain · doi:10.1093/brain/awr179 · Cited by 5,221
Self-citationClassification of primary progressive aphasia and its variants
Gorno-Tempini, M. L., Hillis, A. E., Weintraub, S., Kertesz, A., Mendez, M., Cappa, S. F., Ogar, J. M., Rohrer, J. D., Black, S., Boeve, B. F., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31821103e6 · Cited by 5,141
Self-citationHypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Self-citationImaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Cited by
Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission
Livingston, G., Huntley, J., Liu, K. Y., Costafreda, S. G., Selbæk, G., Alladi, S., Ames, D., Banerjee, S., Burns, A., Brayne, C., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01296-0 · Cited by 3,860
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
Jack, C. R., Andrews, J. S., Beach, T. G., Buracchio, T., Dunn, B., Graf, A., Hansson, O., Ho, C., Jagust, W., McDade, E., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13859 · Cited by 2,803
Self-citationKnopman, D. S., Amieva, H., Petersen, R. C., Chételat, G., Holtzman, D. M., Hyman, B. T., Nixon, R. A., & Jones, D. T. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00269-y · Cited by 2,606
Self-citationThe Amyloid-β Pathway in Alzheimer’s Disease
Hampel, H., Hardy, J., Blennow, K., Chen, C., Perry, G., Kim, S. H., Villemagne, V. L., Aisen, P., Vendruscolo, M., Iwatsubo, T., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01249-0 · Cited by 1,952
Amyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future
Zhang, Y., Chen, H., Li, R., Sterling, K., & Song, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01484-7 · Cited by 988
“In the clinical setting, neuroimaging of sporadic Alzheimer’s patients show the increased cortical tau-PET ligand retention only in the presence of Aβ accumulation, which is also associated with cortical atrophy in AD.(110) In addition, longitudinal studies idenfied that antecedent Aβ aggregates could successfully pre…”
Background
Metadata
- Authors
- Jack, C. R., Wiste, H. J., Botha, H., Weigand, S. D., Therneau, T. M., Knopman, D. S., Graff-Radford, J., Jones, D. T., Ferman, T. J., Boeve, B. F., Kantarci, K., Lowe, V. J., Vemuri, P., Mielke, M. M., Fields, J. A., Machulda, M. M., Schwarz, C. G., Senjem, M. L., Gunter, J. L., & Petersen, R. C.
- Affiliations
- Mayo Clinic (US)
- Department of Neurology, Mayo Clinic, Rochester, MN, USA
- Corresponding author
- Jack, Clifford R
- ORCID
- Jack, Clifford R
- Wiste, Heather J
- Botha, Hugo
- Weigand, Stephen D
- Therneau, Terry M
- Knopman, David S
- Jones, David T
- Ferman, Tanis J
- Boeve, Bradley F
- Kantarci, Kejal
- Lowe, Val J
- Vemuri, Prashanthi
- Mielke, Michelle M
- Fields, Julie A
- Machulda, Mary M
- Schwarz, Christopher G
- Senjem, Matthew L
- Gunter, Jeffrey L
- Petersen, Ronald C
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-09-09
- Volume
- 142
- Issue
- 10
- Pages
- 3230-3242
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC6763736
- OpenAlex
- W2972315303
- Cited by
- 200
- References
- 93
- Citations by year
- 2026: 15 · 2025: 23 · 2024: 31 · 2023: 34 · 2022: 32 · 2021: 31 · 2020: 31 · 2019: 3
- FWCI
- 19.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Brain (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (R37 AG011378, RO1 AG041851, R01 AG056366, R01 NS097495, U01 AG06786, R01 AG034676, P50 AG016574)
- GHR Foundation
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- tau PET, amyloid-beta, bivariate distributions, mild cognitive impairment, frontotemporal dementia, dementia with Lewy bodies, Alzheimer's disease, tauopathy, amyloidosis, standardized uptake value ratio, cognitive aging, neurodegeneration biomarkers, Mayo Clinic Study of Aging, clinical syndromes
- MeSH terms
- Aged, Aged, 80 and over, Aging, Alzheimer Disease, Amyloid, Amyloidosis, Brain, Cognition, Female, Humans, Longitudinal Studies, Male, Middle Aged, Neuropsychological Tests, Biomarkers, Amyloid beta-Peptides, tau Proteins, Neurocognitive Disorders, Tauopathies, Positron-Emission Tomography, Frontotemporal Dementia, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes. https://app.cochat.ai/papers/10.1093/brain/awz268
- The paper
- Jack, C. R., Wiste, H. J., Botha, H., Weigand, S. D., Therneau, T. M., Knopman, D. S., Graff-Radford, J., Jones, D. T., Ferman, T. J., Boeve, B. F., Kantarci, K., Lowe, V. J., Vemuri, P., Mielke, M. M., Fields, J. A., Machulda, M. M., Schwarz, C. G., Senjem, M. L., Gunter, J. L., & Petersen, R. C. (2019). The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes. Brain. https://doi.org/10.1093/brain/awz268
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.